Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68-HBED PSMA

Drug Profile

Gallium-68-HBED PSMA

Alternative Names: (68Ga)PSMA-HBED-CC - Grupo RPH Radiopharmacus; 68Ga-HBED-CC-PSMA - Grupo RPH Radipharmacus; HBED-PSMA-Ga68 - Grupo RPH Radiopharmacus; PSMA-HBED-CC GA-68 - Grupo RPH Radiopharmacus

Latest Information Update: 27 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radiopharmacus
  • Developer Grupo RPH Radiopharmacus
  • Class Imaging agents; Oligopeptides; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 27 Sep 2023 Preclinical development in Prostate cancer is ongoing in Brazil (Grupo RPH pipeline, September 2023)
  • 01 Dec 2016 Radiopharmacus plans a phase III trial for Prostate cancer (diagnosis) in Brazil (RBR26w4cr)
  • 01 Oct 2016 Preclinical trials in Prostate cancer (Diagnosis) in Brazil (IV) before October 2016 (RBR26w4cr)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top